Upper tract urothelial carcinoma · 4 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Gemcitabine (GC) Variant #34 | — | R 15 338 | 56d | — | — | — | — | 1 |
Carboplatin and Gemcitabine (GCb) Variant #01 | — | R 3 663 | 21d | — | — | — | — | 1 |
Observation Partial | — | — | — | — | — | — | — | 2 |
Pirarubicin monotherapy Variant #01 Partial | — | — | — | — | — | — | — | — |
4 of 4 regimens shown